Treatment of Uremic Pruritus With PA101B

Phase 2 Completed 70 enrolled Patara Pharma

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double blind, placebo-controlled, parallel-arm, multi-center, Phase 2, proof-of-concept efficacy and safety study in patients with end-stage renal disease requiring hemodialysis. The purpose of the study is to determine the efficacy and safety profile of PA101B delivered via eFlow high efficiency nebulizer in patients with uremic pruritus who are symptomatic despite using standard treatments.

Timeline

Start: 2016-02
Primary completion: 2016-08
Completion: 2016-12

Publications

Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020 Dec 7;12(12):CD011393. doi: 10.1002/14651858.CD011393.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PA101B	Unknown	40 mg	Inhaled

Indications

No indication recorded.